NCT00492687Unknown2 期
A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas
适应症
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Toxicity
研究概览
简要总结
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Tamoxifen may make tumor cells more sensitive to radiation therapy and chemotherapy. Giving radiation therapy together with temozolomide, tamoxifen, and carboplatin may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects and how well giving radiation therapy together with temozolomide, tamoxifen, and carboplatin works in treating patients with malignant gliomas.
详细描述
OBJECTIVES:
- Determine the progression-free and overall survival of patients with supratentorial malignant gliomas (WHO grade III or IV) receiving radiotherapy with concurrent and adjuvant temozolomide, tamoxifen citrate, and carboplatin.
- Determine the acute and delayed treatment-related toxicities in these patients.
- Determine tumor response in patients with postoperative measurable disease.
OUTLINE: This is an open-label, pilot study.
- Induction therapy: Patients receive oral temozolomide twice daily and oral tamoxifen citrate twice daily on days 1-42 and carboplatin IV over 60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also receive radiotherapy on days 1-5 in weeks 1-6.
- Consolidation therapy: Beginning 4 weeks after the completion of induction therapy, patients receive temozolomide, tamoxifen citrate, and carboplatin as in induction therapy. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 5 years.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed glioblastoma multiforme and/or anaplastic astrocytoma
- •Supratentorial tumor
- •No well-differentiated astrocytoma or glioma with oligodendroglial component
- •No multifocal glioma
- •Has undergone surgery within the past 6 weeks
- •No recurrent glioblastoma multiforme
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-2
- •Neurological functional status 0-2
- •Life expectancy > 12 weeks
- •ANC ≥ 1,200/mm³
- •Platelet count ≥ 100,000/mm³
- •Hemoglobin ≥ 9 g/dL
- •Serum creatinine ≤ 1.5 times upper limit of normal (ULN)
- •Blood urea nitrogen ≤ 1.5 times ULN
- •Total and direct bilirubin ≤ 3 times ULN
- •AST and ALT ≤ 3 times ULN
- •Alkaline phosphatase ≤ 3 times ULN
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 3 months after study completion
- •No other malignancies within the past 3 years, except for carcinoma in situ of the cervix or nonmelanoma skin cancer
- •No acquired immune deficiency syndrome (AIDS)
- •No major medical illness or psychiatric impairment that would preclude study compliance
- •PRIOR CONCURRENT THERAPY:
- •No prior radiotherapy to the head and neck
- •No other concurrent therapy for the tumor
排除标准
- 未提供
结局指标
主要结局
Toxicity
Progression-free survival
Overall survival
Tumor response
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By SurgeryEsophageal CancerNCT00268437Alliance for Clinical Trials in Oncology27
已完成
2 期
Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryPancreatic CancerNCT00112697UNICANCER71
终止
2 期
Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma MultiformeBrain and Central Nervous System TumorsNCT00006916Radiation Therapy Oncology Group19
已完成
2 期
Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma MultiformeBrain and Central Nervous System TumorsNCT00006386Radiation Therapy Oncology Group80
已完成
1 期
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade GliomaBrain and Central Nervous System TumorsNCT00720564City of Hope Medical Center18